GeneBioTech (Korea) Performance
| 086060 Stock | KRW 3,415 65.00 1.94% |
The company retains a Market Volatility (i.e., Beta) of 0.074, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GeneBioTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding GeneBioTech is expected to be smaller as well. At this point, GeneBioTech has a negative expected return of -0.0139%. Please make sure to check out GeneBioTech's coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to decide if GeneBioTech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GeneBioTech Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, GeneBioTech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | 5.9 B |
GeneBioTech |
GeneBioTech Relative Risk vs. Return Landscape
If you would invest 347,500 in GeneBioTech Co on September 19, 2024 and sell it today you would lose (6,000) from holding GeneBioTech Co or give up 1.73% of portfolio value over 90 days. GeneBioTech Co is generating negative expected returns and assumes 1.7255% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than GeneBioTech, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GeneBioTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneBioTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GeneBioTech Co, and traders can use it to determine the average amount a GeneBioTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.008
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 086060 |
Estimated Market Risk
| 1.73 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GeneBioTech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeneBioTech by adding GeneBioTech to a well-diversified portfolio.
GeneBioTech Fundamentals Growth
GeneBioTech Stock prices reflect investors' perceptions of the future prospects and financial health of GeneBioTech, and GeneBioTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneBioTech Stock performance.
| Return On Equity | 0.72 | |||
| Return On Asset | -0.0149 | |||
| Profit Margin | (0.07) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 41.48 B | |||
| Shares Outstanding | 8.37 M | |||
| Price To Earning | 19.69 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 62.81 B | |||
| EBITDA | (24.38 M) | |||
| Cash And Equivalents | 7.43 B | |||
| Total Debt | 2.15 B | |||
| Debt To Equity | 0.15 % | |||
| Book Value Per Share | 3,523 X | |||
| Cash Flow From Operations | (2.84 B) | |||
| Total Asset | 60.37 B | |||
| Retained Earnings | 12.5 B | |||
| Current Asset | 27.77 B | |||
| Current Liabilities | 11.35 B | |||
About GeneBioTech Performance
By analyzing GeneBioTech's fundamental ratios, stakeholders can gain valuable insights into GeneBioTech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GeneBioTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GeneBioTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. The company was founded in 1984 and is headquartered in Gongju, South Korea. GeneBioTech is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about GeneBioTech performance evaluation
Checking the ongoing alerts about GeneBioTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeneBioTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeneBioTech generated a negative expected return over the last 90 days | |
| The company reported the revenue of 62.81 B. Net Loss for the year was (484.4 M) with profit before overhead, payroll, taxes, and interest of 9.43 B. | |
| GeneBioTech Co has accumulated about 7.43 B in cash with (2.84 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
- Analyzing GeneBioTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneBioTech's stock is overvalued or undervalued compared to its peers.
- Examining GeneBioTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneBioTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneBioTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneBioTech's stock. These opinions can provide insight into GeneBioTech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for GeneBioTech Stock analysis
When running GeneBioTech's price analysis, check to measure GeneBioTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneBioTech is operating at the current time. Most of GeneBioTech's value examination focuses on studying past and present price action to predict the probability of GeneBioTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneBioTech's price. Additionally, you may evaluate how the addition of GeneBioTech to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |